Intended for healthcare professionals

  1. Selling sickness: the...
  2. Selling sickness: the pharmaceutical industry and disease mongeringCommentary: Medicalisation of risk factors
Education And Debate

Selling sickness: the pharmaceutical industry and disease mongeringCommentary: Medicalisation of risk factors

BMJ 2002; 324 doi: https://doi.org/10.1136/bmj.324.7342.886 (Published 13 April 2002) Cite this as: BMJ 2002;324:886

Related articles

See more

Cited by...

  • Direct-to-consumer tests advertised online in Australia and their implications for medical overuse: systematic online review and a typology of clinical utility
  • Industry payments to family medicine residents in Portugal: a descriptive analysis of the national transparency database
  • Challenging pharma: who cares?
  • Understanding transnational healthcare use in immigrant communities from a cultural systems perspective: a qualitative study of Dutch residents with a Turkish background
  • Identifying alternative models of healthcare service delivery to inform health system improvement: scoping review of systematic reviews
  • "Asset exchange"--interactions between patient groups and pharmaceutical industry: Australian qualitative study
  • Public, health professional and legislator perspectives on the concept of psychiatric disease: a population-based survey
  • Alternative service models for delivery of healthcare services in high-income countries: a scoping review of systematic reviews
  • Therapeutic alternatives for supporting GPs to deprescribe opioids: a cross-sectional survey
  • Overdiagnosis in primary care: framing the problem and finding solutions
  • Explaining variations in test ordering in primary care: protocol for a realist review
  • Is there a nocebo response that results from disease awareness campaigns and advertising in Australia, and can this effect be mitigated?
  • Ethical drug marketing criteria for the 21st century
  • Does industry-sponsored education foster overdiagnosis and overtreatment of depression, osteoporosis and over{-}active bladder syndrome? An Australian cohort study
  • Walking the tightrope: communicating overdiagnosis in modern healthcare
  • Too much technology
  • There Is No Cure for Existence: On the Medicalization of Psychological Distress
  • Conflict of interest in online point-of-care clinical support websites
  • Diaspora of clinical medicine: Exploring the rift between conventional and alternative health care
  • Navigating the enhancement landscape: Ethical issues in research on cognitive enhancers for healthy individuals
  • What is a disease? Perspectives of the public, health professionals and legislators
  • The truth about sports drinks
  • Preventing overdiagnosis: how to stop harming the healthy
  • Disease, diagnosis or syndrome?
  • Making Sense of Health Care Transformation as Adaptive-Renewal Cycles
  • Physicians, the industry and population health
  • Drug company teaching: summary of responses
  • Fibromyalgia Wars
  • Patients and the public deserve big changes in evaluation of drugs
  • Direct to consumer advertising of prescription drugs
  • Drugs for pre-osteoporosis: prevention or disease mongering?
  • Implications Of Expanding Disease Definitions: The Case Of Osteoporosis
  • The predictability of research in chronic illness
  • Waking up from the DREAM of preventing diabetes with drugs
  • Female genital mutilation: whose problem, whose solution?
  • How NICE may be outflanked
  • Murky waters: the pharmaceutical industry and psychiatrists in developing countries
  • Benefits and harms of direct to consumer advertising: a systematic review
  • Psychiatry and the pharmaceutical industry: who pays the piper?: A perspective from the Critical Psychiatry Network
  • The marketing of a disease: female sexual dysfunction
  • Seeking clarification of osteoporosis guidelines
  • Classifying kidney problems: can we avoid framing risks as diseases?
  • Pharmaco-epidemiology: what do (and don't) we know about utilisation and impact of psychotropic medications in real-life conditions?
  • What is a disease?: Disease, disability and their definitions
  • Family Medicine Research: Implications for Wonca
  • Direct-to-Consumer Advertising: Physicians' Views of Its Effects on Quality of Care and the Doctor-Patient Relationship
  • Ads and prescription pads
  • Annonces et blocs d'ordonnances
  • Is opportunistic disease prevention in the consultation ethically justifiable?
  • Advances in Therapy for Osteoporosis
  • The making of a disease: female sexual dysfunction
  • Estimating the Prevalence of Low Glomerular Filtration Rate Requires Attention to the Creatinine Assay Calibration
  • Alosetron: a case study in regulatory capture, or a victory for patients' rights?
  • Marketing: Celebrity selling---part two
  • The pharmaceutical industry and disease mongering
  • Evolving general practice consultation in Britain
  • Too much medicine?
Back to top